Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →Indications & Uses
Dapaglip is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Adults: The recommended starting dose of Dapagliflozin is 5 mg once daily, taken in the morning, with or without food. In patients tolerating Dapagliflozin 5 mg once daily who require additional glycemic control, the dose can be increased to 10 mg once daily. Patients with Renal Impairment: Assessment of renal function is recommended prior to initiation of Dapagliflozin therapy and periodically thereafter. Dapagliflozin should not be initiated in patients with an eGFR less than 60 mL/min/1.73 m2. No dose adjustment is needed in patients with mild renal impairment (eGFR of 60 mL/min/1.73 m2 or greater). Dapagliflozin should be discontinued when eGFR is persistently less than 60 mL/min/1.73 m2.Children: The safety and efficacy of Dapagliflozin in children and adolescents (<18 years) have not been established.
Side Effects
The most common side effects of Dapaglip includes hypotension, ketoacidosis, acute kidney injury and impairment in renal function, urosepsis and pyelonephritis, hypoglycemia with concomitant use with insulin and insulin secretagogues, genital mycotic infections, increases in low-density lipoprotein cholesterol (LDL-C), nasopharyngitis, urinary tract infection and bladder cancer.
Cautions & Contraindications
Warnings & Precautions
Hypotension: Before initiating Dapaglip, assess volume status and correct hypovolemia in the elderly, in patients with renal impairment or low systolic blood pressure, and in patients on diuretics. Monitor for signs and symptoms during therapy.Impairment in renal function: Monitor renal function during therapy.Hypoglycemia: In patients taking insulin or an insulin secretagogue with Dapaglip, consider a lower dose of insulin or the insulin secretagogue to reduce the risk of hypoglycemia.Bladder Cancer: An imbalance in bladder cancers was observed in clinical trials. Dapaglip should not be used in patients with active bladder cancer and should be used with caution in patients with a prior history of bladder cancer.Macrovascular outcomes: There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with Dapaglip or any other antidiabetic drug.
Contraindications
This product is contraindicated in patients with known hypersensitivity to Dapagliflozin or to any of the excipients. It is also contraindicated in severe renal impairment, end-stage renal diseases or patients on dialysis.